{"id":19007,"date":"2022-03-28T07:55:54","date_gmt":"2022-03-28T14:55:54","guid":{"rendered":"https:\/\/marketdepth.com\/?p=19007"},"modified":"2022-03-28T07:55:56","modified_gmt":"2022-03-28T14:55:56","slug":"staar-surgical-evo-lens-receives-green-light-from-the-fda","status":"publish","type":"post","link":"https:\/\/marketdepth.com\/staar-surgical-evo-lens-receives-green-light-from-the-fda\/","title":{"rendered":"STAAR Surgical EVO Lens Receives Green Light from the FDA"},"content":{"rendered":"\n
STAAR Surgical Company (NASDAQ: STAA)<\/strong> today announced <\/a>that the U.S. Food and Drug Administration (FDA) approved the EVO\/EVO+ Visian\u00ae Implantable Collamer\u00ae Lens (“EVO”) for the correction of myopia and myopia with astigmatism.<\/p>\n\n\n\n Shares of STAAR Surgical Company (NASDAQ: STAA) gained over 14% in premarket trading following the announcement.<\/p>\n\n\n\n An estimated 100 million U.S. adults ages 21 to 45 who have myopia are potential candidates for EVO, a biocompatible implantable lens that corrects distance vision, according to the Company\u2019s press release. “Over one million EVO lenses have already been implanted by doctors outside the U.S. and 99.4% of EVO patients in a survey have stated they would have the procedure again,\u201d said Caren Mason, President and CEO of STAAR Surgical.<\/p>\n\n\n\n EVOs are implanted within the posterior chamber of the eye directly behind the iris and in front of the natural crystalline lens, and there are more than 100 clinical papers available discussing the safety and efficacy of the Visian ICL family of lenses globally.<\/p>\n\n\n\n “We are thrilled to make EVO available to U.S. surgeons and patients seeking a proven and premium option to glasses, contact lenses or laser vision correction.\u201d<\/p>Scott D. Barnes, MD, Chief Medical Officer of STAAR Surgical<\/cite><\/blockquote>\n\n\n\n Commercialization of EVO is expected to begin immediately in the U.S. and, according to President and CEO of STAAR Surgical, Caren Mason, \u201cSurgeons will be trained and certified for EVO, and begin implanting EVO in the coming days and weeks in select cities.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"STAAR Surgical Company (NASDAQ: STAA) today announced that the U.S. Food and Drug Administration (FDA) approved the EVO\/EVO+ Visian\u00ae Implantable Collamer\u00ae Lens (“EVO”) for the correction of myopia and myopia with astigmatism. Stock Gains Premarket Shares of STAAR Surgical Company (NASDAQ: STAA) gained over 14% in premarket trading following the announcement. Over 1Million Lenses Implanted… View Article<\/a>","protected":false},"author":3,"featured_media":19008,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":0,"footnotes":""},"categories":[9,31,17,8,11,16],"tags":[],"acf":[],"yoast_head":"\nStock Gains Premarket<\/h5>\n\n\n\n
Over 1Million Lenses Implanted<\/h5>\n\n\n\n
Implanted in The Posterior of Eye<\/h5>\n\n\n\n